Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 11.11 is in line with its 1-year average of 10.39, near the high end of its 1-year range (9.67–11.11).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly quick ratio; no daily interpolation.
Limited quarterly history available
Quick Ratio needs at least three reported quarters before a meaningful chart is shown.
QUICK RATIO (ACID-TEST)
11.11
QUICK RATIO (ACID-TEST) AVG TTM
N/A
QUICK RATIO (ACID-TEST) AVG 3Y
N/A
QUICK RATIO (ACID-TEST) AVG 5Y
N/A
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.19
median of 733 covered companies
CURRENT VS SECTOR MEDIAN
+248.20%
vs the sector median at left
Kailera Therapeutics, Inc.
Market Cap
$1.40B
Quick Ratio (Acid-Test)
11.11
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.40B
Quick Ratio (Acid-Test)
5.07
TTM Avg
3.94
3Y Avg
5.82
5Y Avg
6.31
Market Cap
$1.42B
Quick Ratio (Acid-Test)
1.20
TTM Avg
1.17
3Y Avg
1.13
5Y Avg
1.04
Market Cap
$1.43B
Quick Ratio (Acid-Test)
5.61
TTM Avg
9.29
3Y Avg
11.65
5Y Avg
16.84
Market Cap
$1.43B
Quick Ratio (Acid-Test)
1.56
TTM Avg
2.29
3Y Avg
2.59
5Y Avg
3.62
Market Cap
$1.35B
Quick Ratio (Acid-Test)
35.85
TTM Avg
18.03
3Y Avg
18.03
5Y Avg
18.03
Market Cap
$1.36B
Quick Ratio (Acid-Test)
1.94
TTM Avg
2.22
3Y Avg
2.95
5Y Avg
3.44
Market Cap
$1.45B
Quick Ratio (Acid-Test)
18.31
TTM Avg
12.63
3Y Avg
8.12
5Y Avg
8.12
Market Cap
$1.46B
Quick Ratio (Acid-Test)
2.94
TTM Avg
3.04
3Y Avg
2.84
5Y Avg
2.90
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | $1.40B | 11.11 | N/A | N/A | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.40B | 5.07 | 3.94 | 5.82 | 6.31 |
| The Pennant Group, Inc. (PNTG)vs › | $1.42B | 1.20 | 1.17 | 1.13 | 1.04 |
| AnaptysBio, Inc. (ANAB)vs › | $1.43B | 5.61 | 9.29 | 11.65 | 16.84 |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.43B | 1.56 | 2.29 | 2.59 | 3.62 |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.35B | 35.85 | 18.03 | 18.03 | 18.03 |
| Omeros Corporation (OMER)vs › | $1.36B | 1.94 | 2.22 | 2.95 | 3.44 |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.45B | 18.31 | 12.63 | 8.12 | 8.12 |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.46B | 2.94 | 3.04 | 2.84 | 2.90 |
| Certara, Inc. (CERT)vs › | $1.46B | 2.55 | 2.09 | 2.53 | 2.95 |
Quick Ratio
11.11
Excludes inventory
Current Ratio
11.11
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 11.11 |
| 2026-03-31 | 9.67 |
